L26/O-238 Reclaiming possibility: patient perspectives on transferring embryos labeled “abnormal” by PGT-A and the ethical and legal implications
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Takahashi und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Study question What ethical-informational gaps arise when patients transfer embryos labelled “abnormal” by preimplantation genetic testing for aneuploidy (PGT-A) after institutional refusal? How do these shape decision-making? Summary answer Transfers of embryos labelled “abnormal” reflect structured patient decision-making under uncertainty and reveal inconsistent clinical counseling, opaque policies, and systemic governance gaps surrounding PGT-A. What is known already PGT-A is widely used in IVF despite ongoing debate regarding its clinical utility, interpretation, and impact on cumulative live birth rates (LBR). Many clinics categorically refuse transfer of embryos labelled “abnormal,” even though reports document healthy live births following transfer of selected embryos labelled “mosaic” or “aneuploid.” Considerable heterogeneity exists in PGT-A reporting, counseling practices, and downstream clinical decisions. Patient perspectives on navigating diagnostic uncertainty, institutional constraints, and ethical responsibility in decisions to transfer “abnormal” embryos remain largely unexplored. Study design, size, duration This qualitative study used semi-structured interviews conducted between 2019 and 2024. Reflexive thematic analysis explored patient experiences, ethical reasoning, and decision-making related to transferring embryos labelled “abnormal” by PGT-A. Clinical outcomes were reviewed descriptively to contextualize narratives. Participants/materials, setting, methods Participants (n = 21) underwent autologous IVF and elected to transfer embryos reported “abnormal” following PGT-A at our academic fertility center, often after refusal elsewhere. All received extensive counseling and provided enhanced informed consent. Interviews were recorded, transcribed, and analyzed using reflexive thematic analysis, and triangulated with pregnancy and prenatal diagnostic outcomes. Main results and the role of chance Analysis identified an overarching theme, “reclaiming possibility,” reflecting efforts to preserve reproductive options under diagnostic uncertainty and institutional constraint. Four phases emerged. First, patients reassessed scientific authority after treatment failures and exposure to inconsistent PGT-A policies, prompting re-evaluation of test reliability. Second, participants navigated institutional barriers, including categorical transfer refusals driven by liability concerns and performance metrics, shifting risk and cost onto patients. Third, decisions to transfer “abnormal” embryos were framed as ethically deliberate, grounded in responsibility, proportional risk assessment, and lack of alternatives. Fourth, participants reported retrospective validation and closure regardless of outcome, alongside persistent skepticism regarding PGT-A’s predictive certainty. In established pregnancies, non-invasive prenatal testing at 11–12 weeks and confirmatory invasive testing at 14–16 weeks demonstrated normal fetal karyotypes, followed by healthy live births in all cases. Participants consistently reported insufficient pre-test counseling and lasting psychosocial effects of embryo labeling. Limitations, reasons for caution This single-center qualitative study involved a selected population and may not capture broader perspectives. Clinical outcomes were descriptive and not designed to assess efficacy, although thematic saturation supports transferability of insights. Wider implications of the findings Findings support uncertainty-aware pre-test informed consent and transparent clinic policies for transfer of embryos labelled “abnormal” by PGT-A. Governance frameworks should standardize communication of uncertainty and decision pathways, while post-transfer registries may reduce harm and improve patient-centered care. Trial registration number No
Zitieren
APA
Takahashi, S., Gayete-Lafuente, S., Guijarro-Baude, L., Choong, E., Dunn, M., Savulescu, J., Patrizio, P., Barad, D., & Gleicher, N. (2026). L26/O-238 Reclaiming possibility: patient perspectives on transferring embryos labeled “abnormal” by PGT-A and the ethical and legal implications. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.236
Vancouver
Takahashi S, Gayete-Lafuente S, Guijarro-Baude L, Choong E, Dunn M, Savulescu J, et al. L26/O-238 Reclaiming possibility: patient perspectives on transferring embryos labeled “abnormal” by PGT-A and the ethical and legal implications. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.236
BibTeX
@article{Takahashi2026,
author = {Takahashi, S. and Gayete-Lafuente, S. and Guijarro-Baude, L. and Choong, E. and Dunn, M. and Savulescu, J. and Patrizio, P. and Barad, D. and Gleicher, N.},
title = {L26/O-238 Reclaiming possibility: patient perspectives on transferring embryos labeled “abnormal” by PGT-A and the ethical and legal implications},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.236}
}
EUVIMED